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Abstract
Background: Due to tolerance development and adverse side effects, chronic pain patients
frequently need to be switched to alternative opioid therapy
Objective: To assess the efficacy and tolerability of an alternative transdermally applied (TDS)
opioid in patients with chronic cancer pain receiving insufficient analgesia using their present
treatment.
Methods: A total of 32 patients received alternative opioid therapy, 16 were switched from
buprenorphine to fentanyl and 16 were switched from fentanyl to buprenorphine. The dosage used
was 50% of that indicated in equipotency conversion tables. Pain relief was assessed at weekly
intervals for the next 3 weeks
Results: Pain relief as assessed by VAS, PPI, and PRI significantly improved (p < 0.0001) in all
patients at all 3 follow up visits. After 3 weeks of treatment, the reduction in the mean VAS, PPI,
and PRI scores in the fentanyl and buprenorphine groups was 68, 77, 74, and 69, 79, and 62%,
respectively. Over the same time period the use of oral morphine as rescue medication was
reduced from 27.5 ± 20.5 (mean ± SD) to 3.75 ± 8.06, and 33.8 ± 18.9 to 3.75 ± 10.9 mg/day in
the fentanyl and buprenorphine groups, respectively. There was no significant difference in either
pain relief or rescue medication use between the two patient groups The number of patient with
adverse events fell during the study. After the third week of the treatment the number of patients
with constipation was reduced from 11 to 5, and 10 to 4 patients in the fentanyl and buprenorphine
groups, respectively. There was a similar reduction in the incidence of nausea and vomiting. No
sedation was seen in any patient after one week of treatment.
Conclusion: Opioid switching at 50% of the calculated equianalgesic dose produced a significant
reduction in pain levels and rescue medication. The incidence of side effects decreased and no new
side effects were noted. Further studies are required to provide individualized treatment for
patients according to their different types of cancer.
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Introduction
Opioids represent the principal therapy in chronic moder-
ate to severe cancer pain treatment. The development of
transdermal polymer matrix systems for opioid adminis-
tration has resulted in several advantages compared to
oral, sublingual or parenteral administration. These sys-
tems represent a non-invasive method, effective and well
accepted by cancer patients who often have gastrointesti-
nal problems and difficulties with oral medication (e.g.
oesophageal, gastric, intestinal or maxillofacial cancer)
either due to the cancer itself or due to the side-effects on
oral or parenteral concomitant medication [1]. At present,
the opioids buprenorphine and fentanyl are available in
transdermal formulations.
Recent studies have shown that opioid transdermal deliv-
ery systems have numerous advantages since they permit
continuous controlled release of the opioid for 72, or even
up to 96 hours depending on the product, thus reducing
peaks in plasma drug concentrations resulting in consist-
ent and long-term pain relief. In addition, they are associ-
ated with a lower rate of adverse events. Overall, they
represent a very useful therapy since they offer adequate
analgesia with comparably low side-effects and non-inva-
sive administration. However, analgesic tolerance can
develop with any long-term opioid treatment, requiring
an increase in drug dosage in order to obtain the same
analgesic effect. As a consequence this normally results in
an increase in side effects [2,3]. In cases where patients are
not achieving satisfactory analgesia, or are suffering from
intolerable side-effects, the guidelines of the World
Health Organization for cancer pain treatment recom-
mend switching to an alternative opioid. For many
patients opioid switching or rotation is the only solution
for pain relief [4,5]. Prior to the introduction of a new for-
mulation it is necessary to establish an approximate dose
ratio to provide an equivalent analgesic effect.
Considering the importance of this strategy, we carried
out this study on opioid switching using two polymer
matrix systems: transdermal buprenorphine (BTDS) and
transdermal fentanyl (FTDS) substituting the opioid pre-
viously taken with the other type (e.g. FTDS if they were
originally taking BTDS, and vice versa) in patients who
were dissatisfied with their previous therapy with respect
to inadequate analgesia, side-effects or both. Based on
previously published data and considering the mecha-
nisms which form the basis of tolerance phenomena, the
aim of this study was to evaluate the switching dose
between transdermal opioids, with regard to analgesic
efficacy and the reduction of side-effects.
Patients and methods
Patients
Eligible patients, of either sex, were suffering from chronic
pain and had been treated for the previous three months
with either transdermal buprenorphine or transdermal
fentanyl. Inclusion criteria required inadequate analgesia
(Visual Analogue Scale [VAS] > 50 mm, and the presence
of adverse events correlating with opioid analgesic treat-
ment (sedation, dysphoria, nausea/vomiting and consti-
pation).
Exclusion criteria included renal insufficiency (serum cre-
atinine clearance less than 60 ml/min), moderate or
severe hepatic disease (Child-Pugh score between 7 and
10 or between 10 and 15, respectively), history of hepati-
tis B or C, or acute hepatitis A in the last three months,
HIV, clinically significant cardiovascular and/or respira-
tory diseases, pregnancy, lactation, alcohol consumption,
psychotropic drug consumption. Also excluded were
patients expecting chemotherapy or radiotherapy cycles
during the study, those with known allergy to the medi-
cines or matrix patch components, those with extensive
skin disease, and patients who were currently participat-
Mean Weekly VAS Figure 1
Mean Weekly VAS.
Table 1: Demographic Data of Enrolled Patients[SN6]
Sex
Male 17
Female 15
Age
Mean 62
Range 42–78
Cancer Site
Lung 8
Colon 2
Stomach 5
Bladder 1
Breast 1
Prostate 11
Gall Bladder 2
Brain primitive cancer 2Journal of Experimental & Clinical Cancer Research 2009, 28:61 http://www.jeccr.com/content/28/1/61
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ing in, or had within the last 30 days participated in, other
clinical trials. Patients with neurological and/or psycho-
logical conditions that might hinder completing daily dia-
ries and pain scales were also excluded.
Study procedure
The study was carried out according to the ethical princi-
ples of the current amended version of Declaration of Hel-
sinki, after ethics committee approval. All the patients
gave their signed informed consent before participation in
the study.
The four-week study was organized with a Screening visit
(V0) followed by a Recruitment visit (V1) one week later,
when treatment was initiated. Three control visits (V2, V3,
and V4) at weekly intervals then followed.
During the screening visit (V0) the age, sex and race of
each patient was noted and a detailed history of the cancer
disease and of the concomitant pain was taken. Each
patient underwent a thorough a physical examination
including height, weight and vital signs (blood pressure,
respiratory frequency and heart rate). The presence or
absence of other concomitant disease and their treatment
was registered. Haematochemical analyses were carried
out to evaluate hepatic and renal function (Transaminase,
Electrolytes, Urea, Creatinine, Cholinesterase, Pro-
thrombin and Partial Thromboplastin time, International
Normalised Ratio) (Cr, NA, K, BU, GPT, GOT, γGT, CHE,
PT, aPTT, INR). An ECG was performed together with a
neurological examination. During the visit the type of
transdermal patch and the dose were noted.
At the end of the screening visit the patients were dis-
charged and told to continue the previous therapy. They
were asked to return to the department for the recruitment
visit one week later. All the patients received a diary in
which to rate their pain every morning on awakening on
a VAS scale. Patients were permitted to continue with res-
cue medication (20 mg oral immediate release (IR) mor-
phine) up to a maximum of three daily doses, which was
recorded in the diary.
During the recruitment visit each patient underwent a
thorough physical examination: general appearance, eyes,
lungs, heart, abdomen, musculoskeletal and vital signs
were evaluated. The results of haematochemical examina-
tions for renal and hepatic function and the results of the
neurological and cardiological examinations were
recorded. Adverse Events (AEs) were evaluated. The con-
sumption of rescue medication in mg/day was recorded.
Patients complying with the inclusion criteria were
divided into two groups according to the administered
therapy up to the recruitment visit. The method used for
transdermal patch switching was to replace the first opioid
patch with the alternative one, deducting 50% from the
dose calculated according to equianalgesic tables.
The FTDS group were patients at the screening visit who
had taken buprenorphine TDS 70 μg/h and suffered side-
effects and refractory pain and had taken this dose contin-
uously during the pre-recruitment week. At the recruit-
ment visit, the transdermal buprenorphine patch in these
patients was replaced by a 25 μg/h transdermal fentanyl
patch, positioned at different skin site on the thorax, arm
or back.
The BTDS group were patients at the screening visit who
had taken fentanyl TTS 75 μg/h and suffered side-effects
and refractory pain and had taken this dose continuously
during the pre-recruitment week. The transdermal fenta-
nyl patch in these patients was replaced by a 52.5 μg/h
transdermal buprenorphine patch, positioned at different
skin site on the thorax, arm or back.
Rescue medication with 20 mg of immediate-release oral
morphine was prescribed to each patient up to three times
a day. At the end of the recruitment visit (V1) all the
patients were asked to return after one week for the first
Table 2: 
Mean VAS ± SD Mean PPI ± SD Mean PRI ± SD
V1 V2 V3 V4 V1 V2 V3 V4 V1 V2 V3 V4
FTDS 66.9 ± 
14.0
44.4 ± 
14.1
28.8 ± 
13.6
21.2 ± 
12.0
3.50 ± 
0.89
1.62 ± 
0.72
1.0 ± 0.63 0.81 ± 
0.66
32.4 ± 
2.13
24.2 ± 
6.46
14.4 ± 
4.01
11.6 ± 
1.59
% 
reduction 
from V1
34 57 68 54 71 77 35 66 74
p <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
BTDS 67,5 ± 
13,4
45.0 ± 
11.5
26.9 ± 
10.8
21.2 ± 
13.6
3.5 ± 0.82 1.44 ± 
0.63
0.88 ± 
0.81
0.75 ± 
0.86
33.1 ± 
1.91
22.1 ± 
7.18
18.3 ± 
4.66
12.5 ± 
1.97
% 
reduction 
fromV1
33 60 69 59 75 79 43 45 62
P <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001Journal of Experimental & Clinical Cancer Research 2009, 28:61 http://www.jeccr.com/content/28/1/61
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control visit (V2), and to continue keeping their daily dia-
ries.
Assessment of analgesic efficacy
Mean weekly pain on the basis of the VAS scores in diaries
(VAS 0 = no pain to VAS 100 = intolerable pain) was
recorded throughout the 4 week period. The Present Pain
Intensity (PPI, 0 = no pain, 1 = mild, 2 = discomforting, 3
= distressing, 4 = horrible, 5 = excruciating) and Pain Rat-
ing Index (PRI) were assessed during each visit from V1 to
V4. The PRI was taken from the Short-Form Mc Gill Pain
Questionnaire and comprised 15 items investigating both
the sensorial (11 items) and the emotional sphere of pain
(4 items) with a score from 0 to 3 for each item (0–45). In
all cases the necessity of rescue medication was registered
as milligrams of oral morphine per day. Another parame-
ter taken into consideration was the patients' satisfaction
with the new therapy. It was evaluated by means of the
simple question: "Are you satisfied with your analgesic
treatment?" The patients could answer only "Yes/No".
The primary efficacy measure was pain reduction as
recorded by patients both in a daily dairy using VAS and
during the visits by PPI and PRI. The secondary efficacy
measure was the reduction of rescue mediation consump-
tion as milligrams of IR oral morphine per day.
Assessment of adverse events
In all patients, the presence (Yes) or absence (No) of AEs
was evaluated and recorded in response to questions
posed for nausea and/or vomiting, constipation, and dys-
phoria. The level of sedation was evaluated by a 4-point
scale (0 = no sedation, 1 = slight sedation, 2 = moderate
sedation, 3 = severe sedation).
Statistical analysis
For each of the two treatment groups, a paired Student t
test was used to compare the mean values of the primary
efficacy parameters (VAS, PPI, and PRI) and rescue medi-
cation consumption for the same patients measured at
Visits 2, 3, and 4 compared to baseline values (Visit 1). A
Student t test for independent variables was used to com-
pare the two independent treatment groups.
Results
In total, 40 Caucasian patients were screened and 32 were
enrolled. All the enrolled patients completed the study.
The demographic characteristics of the patients are shown
in table 1.
There were no differences in vital signs and no respiratory
depression was noted in either group. No significant dif-
ferences were showed between Group BTDS and Group
FTDS regarding VAS, PPI, PRI values, AEs incidence and
rescue medication consumption on enrolment.
Analgesic efficacy
In both groups of patients, there was a statistically signifi-
cant reduction (p < 0.0001) of the weekly VAS after 1, 2
and 3 weeks treatment compared to V1 values. The mean
decrease in the FDTS group was 34% (V2), 57% (V3) and
Mean of daoli milligrams of IR oral Morphine recorded each  visit Figure 4
Mean of daoli milligrams of IR oral Morphine 
recorded each visit.
Mean Weekly PPI Figure 2
Mean Weekly PPI.
Mean Weekly PRI Figure 3
Mean Weekly PRI.Journal of Experimental & Clinical Cancer Research 2009, 28:61 http://www.jeccr.com/content/28/1/61
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68% (V4), and in the BTDS group was 33% (V2), 60%
(V3), 69% (V4) (table 2 and figure 1). The was no statisti-
cally significant difference between the two groups at any
visit.
In both groups of patients, there was a statistically signifi-
cant reduction in the PPI score (p < 0.0001) at each visit
after commencing treatment. The mean decrease in the
FTDS group was 54% (V2), 71% (V3), and 77% (V4), and
in the BTDS group 59% (V2), 75% (V3), and 79% (V4)
(table 2 and figure 2). There was no statistically significant
difference between the two groups at any visit.
A significant reduction was also observed in PRI. (p <
0.0001) as showed in table 2 and figure 3. The mean
decrease in the FTDS group was 35% (V2), 66% (V3), and
74% (V4), and in the BTDS group 43% (V2), 45% (V3),
and 62% (V4). There was no statistically significant differ-
ence between the FTDS and BTDS groups at any visit.
In all patients there was a reduction in rescue medication
at Visits 2, 3, and 4 as measured by the daily consumption
of IR oral morphine (figure 4). This was statistically signif-
icant (p < 0.0001) at V3 and V4 in both treatment groups
(Table 3). There was no significant difference between the
two patient groups.
Patients of both groups stated that they were satisfied with
the therapy, in fact all the patients answered yes to the
question: "Are you satisfied with your analgesic treat-
ment?"
Adverse events
Transdermal opioid switching reduced the incidence of
adverse events. Nausea and vomiting persisted in patients
suffering from gall bladder cancer and gastric cancer
(three patients). The number of patients with constipa-
tion was also reduced; BTDS group: V1 11 pts, V2 4 pts, V3
5 pts, V4 5 pts and similarly in the FTDS group: V1 10 pts,
V2 6 pts, V3 4 pts, V4 5 pts (table 4 and table 5). Consti-
pation persisted only in patients suffering from colon,
brain and lung cancer (9 patients). Moreover, in both
groups, dysphoria and sedation disappeared completely
after the first week (tables 4 and 5).
Discussion
Opioid switching is a fundamentally useful strategy in
long-term treatment of cancer pain, where tolerance phe-
nomena and the large number of side-effects can limit the
use of these medicines and further diminish the patients'
quality of life [6,8]. In these cases, switching from one
opioid to another is a useful means to establish a more
favourable balance between analgesia and toxicity and is
regulated in conversion tables in order to ensure fewer
side-effects and an improvement in pain symptoms.
[7,9,10,12].
The development of tolerance suggests the necessity to
increase the drug dose in order to obtain the same analge-
sic effect [13,14]. Tolerance development may also be
associated with pharmacodynamic, pharmacokinetic and
psychological processes resulting in an increase in side
effects connected not only with the drug, but also with its
metabolites. It may be supposed that by changing the opi-
oid and using lower doses than indicated in conversion
tables it is possible, in most cases, to reduce toxicity and
improve pain symptoms [6,15,16].
According to available data, many factors may influence
opioid treatment such as individual variability, genetic
factors, relation among active metabolites, intrinsic activ-
ity, number and types of receptors, as well as issues of effi-
cacy, toxicity and tolerance. Considering the above cited
variables and the importance of an individualized treat-
Table 4: 
Number of patients with Nausea and/or vomiting Number of patients with constipation Number of patients with dysphoria
V1 V2 V3 V4 V1 V2 V3 V4 V1 V2 V3 V4
F T D S 9 6 5 3 1 06 4 5 0000
B T D S 8 5 4 2 1 14 5 4 2000
Table 3: RESCUE MEDICATION (mean mg/day for each group ± SD)
RESCUE MEDICATION (mean mg/day for each group ± SD)
V1 V2 V3 V4
FTDS 27.5 ± 20.5 16.2 ± 18.24 5.0 ± 13.7 3.75 mg ± 8.06
p value compared to V1 0.095 0.002 <0.0001
BTDS 33.8 ± 18.9 16.2 ± 20.9 3.75 ± 10.9 3.75 ± 10.9
p value compared to V1 0.058 <0.0001 <0.0001Journal of Experimental & Clinical Cancer Research 2009, 28:61 http://www.jeccr.com/content/28/1/61
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ment, we decided to switch buprenorphine TDS with fen-
tanyl TDS, and vice versa, in order to utilize the particular
characteristics of these two opioids, without changing
route of administration [17].
Our data indicated that by switching buprenorphine TDS
to fentanyl TDS and vice versa, with a 50% reduction of
the new opioid dose over that given in the conversion
tables we obtained a significant reduction of both pain
and rescue medication. Moreover, side effects decreased
and no new side effects became apparent.
Our results are a starting point for further studies and reit-
erate the importance of providing individualized treat-
ment and taking the site of the cancer into account (the
three patients who still had nausea and vomiting had gas-
tric and gall bladder cancer). This applies not only to the
therapeutic formulation but also to the side effect analy-
sis, so that we can gain a better understanding of how
much the adverse events are connected with the choice of
opioid and how much they are related, or supported by,
the underlying pathology of the disease.
In our study we decided to change the drug and not the
route of administration, because patients prefer a
transdermal route as it does not interfere with their daily
activities, it is easy to use, and is non invasive. Transder-
mal route patients only have to remember their opioid
medication every 72 hours. Reduced constipation, nausea
and vomiting result in a better quality of life. These factors
account for better patient compliance and lead to the feel-
ing of greater independency from treatment. All patients
stated that they were satisfied with the therapy and this
result is particularly important because, as the interna-
tional literature underlines, psychological factors interfere
with patients' quality of life and disease prognosis [13,18-
20].
In contrast with our results, other studies discuss the
necessity of using equianalgesic doses in opioid switching
to obtain good pain control [16]. These differences sug-
gest that the drug, its formulation, individual response
and the route of administration are all variables of funda-
mental importance in the therapeutic result, and that the
response to opioids does not depend on the pathophysi-
ology of the pain alone, but rather a complex phenome-
non linked to individual factors.
Conclusion
In conclusion, we think that further studies should be per-
formed in order to find safe and effective opioid switching
methods necessary to give greater insight into the difficult
balance between analgesia and toxicity. It is also impor-
tant to consider individual variables, such as psychologi-
cal distress in cancer patients, as these are important as
prognostic factors since they affect therapeutic results.
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